Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEnsilica Regulatory News (ENSI)

Share Price Information for Ensilica (ENSI)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -10.50 (-9.59%)
Bid:
99.00
Ask:
101.00
Spread: 2.00 (2.02%)
Market Cap: £116.70m
ENSI Live PriceLast checked at - London Stock Exchange

Intraday Ensilica Share Chart

New Contract Wins and Programme Upgrades

10 Mar 2026 07:00

RNS Number : 9447V
EnSilica PLC
10 March 2026
 

THIS ANNOUNCMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR") AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR

 

10 March 2026

 

EnSilica plc

("EnSilica", the "Company" or the "Group")

 

New Contract Wins and Programme Upgrades

 

EnSilica plc (AIM: ENSI), a leading fabless, application-specific chipmaker, is pleased to provide an update on recent contract wins and programme upgrades, which continues to underpin the Company's mid-term outlook.

 

New Contract Win for Life-Science Analysis Systems

 

EnSilica has secured a design implementation and manufacturing contract with a leading UK publicly quoted life-sciences technology company.

 

Under this contract win, EnSilica will provide semiconductor design implementation expertise alongside tape-out management and wafer manufacturing services for a next-generation chip used within advanced life-science analysis systems. The semiconductor will be manufactured at a leading semiconductor foundry, with EnSilica providing the customer with direct access and technical support.

 

The initial contract value, including engineering services and prototype wafer supply, is approximately US$1.6 million with material revenue contributions commencing in the financial year ending 31 May 2027 ("FY 2027"), with the potential of future additional long-term revenue from future production wafer supply.

 

New Contract for Wireless Healthcare ASIC Feasibility Study

 

EnSilica has been awarded a fully funded feasibility study contract by a U.S. healthcare technology company to develop a wireless biosensing and therapeutic controller ASIC. The end application uses cloud-based AI to support treatment for chronic conditions.

 

The feasibility study has a value of approximately US$200,000 and leverages EnSilica's existing eSi-Sense healthcare technology platform. The study is scheduled to commence in May 2026 and will run for 3 months. A successful study is expected to lead to a multi-million-dollar design and supply agreement.

 

Upgrade and Extension of Existing Automotive ASIC Programme

 

The Company is pleased to report an increase in forecast demand for calendar years 2026 to 2028 for its existing automotive ASIC contract with a premier global OEM brand. This increase in volumes is expected to generate additional revenues in excess of US$4 million over calendar years 2026 and 2028.

 

The Company is also pleased to report that production volumes for this programme are now expected to extend beyond 2030, increasing the estimated lifetime value of the programme to in excess of the previously forecast value of US$40 million.

 

Outlook

 

These new engagements and programme updates further strengthen the Company's confidence in achieving market consensus forecasts for the current financial year ending 31 May 2026 ("FY 2026") as well as FY 2027.

 

The Board remains confident of delivering a substantial increase in revenues and EBITDA profitability for FY 2026 and reiterates its current guidance for FY 2026 of revenues of between £28 million to £30 million and EBITDA profits of between £3.5 million and £4.5 million.

 

Ian Lankshear, Chief Executive Officer of EnSilica, commented:

 

"These new contract wins and programme upgrades reflect the continued demand for EnSilica's capabilities across our key growth markets, including multiple engagements across the satellite communications arena. 

 

This encouraging momentum further strengthens our revenue visibility and supports the Board's confidence in the Company delivering sustained revenue growth and generating near-term cash-generation."

 

EnSilica plc

Ian Lankshear, Chief Executive Officer

Kristoff Rademan, Chief Financial Officer

www.ensilica.com

via Vigo Consulting

+44 (0)20 7390 0233

 

Allenby Capital Limited (Nominated Adviser & Joint Broker)

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

Joscelin Pinnington / Tony Quirke (Sales & Corporate Broking)

 

 

+44 (0)20 3328 5656

info@allenbycapital.com

Panmure Liberum Limited (Joint Broker)

Edward Mansfield / Will King / Phoebe Bunce

 

+44 (0)20 3100 2000

 

 

Vigo Consulting (Investor & Financial Public Relations)

Jeremy Garcia/ Safia Colebrook

 

+44 (0)20 7390 0233 

ensilica@vigoconsulting.com

 

The person responsible for arranging release of this announcement on behalf of the Company is Ian Lankshear, Chief Executive Officer.

 

About EnSilica plc

EnSilica is a fabless, application-specific chipmaker, combining deep domain and system-level expertise with world-class capability in RF, mmWave, mixed-signal and complex digital IC design. The Company serves customers across the space and communications, industrial, automotive and healthcare markets, where safety and security and reliability are critical.

A growing portfolio of reusable IP and silicon platforms underpins a repeatable, scalable delivery model, reducing development risk, cost and time to market while supporting long-term supply revenues. EnSilica has a strong track record of delivering production-proven silicon to demanding industry standards. Headquartered near Oxford, UK, the Company operates design centres across the UK, India, Brazil and Hungary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKCBKCBKDCNK
Date   Source Headline
1st Jun 20267:00 amRNS$75m Contract Win
11th May 20262:50 pmRNSHolding(s) in Company
7th May 20267:00 amRNSHolding(s) in Company
5th May 20265:35 pmRNSHolding(s) in Company
30th Apr 20265:30 pmRNSTotal Voting Rights
23rd Apr 20267:00 amRNSMajor SpaceTech Contracts
15th Apr 20267:00 amRNSCross-Trading on the U.S. OTCQX Market
7th Apr 202611:26 amRNSResult of GM, Major New Shareholder and TVR
31st Mar 20265:00 pmRNSTotal Voting Rights
31st Mar 20267:00 amRNS-REnSilica selected for UK CHERI Adoption Collective
30th Mar 20261:20 pmRNSIntention for shares to trade on the OTCQB Market
24th Mar 202611:17 amRNSHolding(s) in Company
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20267:00 amRNSResult of Retail Offer & Notice of GM
17th Mar 202612:55 pmRNSHoldings in Company
13th Mar 20267:01 amRNSRetail Offer to raise up to £0.3 million
13th Mar 20267:01 amRNSRetail Offer to raise up to £0.3 million
13th Mar 20267:00 amRNSResult of oversubscribed Placing and Subscription
13th Mar 20267:00 amRNSResult of oversubscribed Placing and Subscription
12th Mar 20264:35 pmRNSProposed equity fundraising via ABB
10th Mar 20267:00 amRNSNew Contract Wins and Programme Upgrades
4th Mar 202612:50 pmRNS-RUK Gov Furthers Investment in Satellite Comms
23rd Feb 20265:02 pmRNSHolding(s) in Company
5th Feb 20267:00 amRNSProduction Milestone Achieved on Siemens Contract
3rd Feb 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSNotice of Results & Investor Presentation
7th Jan 20267:00 amRNSH1 FY 2026 Trading Update
27th Nov 202512:00 pmRNSResult of Annual General Meeting
27th Nov 20257:00 amRNSAGM Statement
24th Nov 20257:00 amRNS$1.4m Purchase Order for Satellite Payload ASIC
13th Nov 20254:05 pmRNSEnSilica to develop critical infrastructure chip
4th Nov 20257:00 amRNSAudited Results for the Year Ended 31 May 2025
3rd Nov 20257:00 amRNSProject Progress Update and New Contract Awards
17th Oct 20252:57 pmRNSHolding(s) in Company
16th Oct 20257:00 amRNSTrading Update
8th Oct 20257:00 amRNSNotice of Annual Results & Investor Presentation
7th Oct 20254:27 pmRNSAIM Rule 17 notification
12th Aug 20257:00 amRNS-RNew EU Mixed Signal Design Centre in Budapest
16th Jul 20257:00 amRNSGrants of Options under Long Term Incentive Plan
1st Jul 20257:00 amRNSAppointment of Joint Broker
16th Jun 20257:00 amRNSHolding(s) in Company
12th Jun 20257:00 amRNSContract Update
28th May 20257:00 amRNS-REnSilica Establishes Engineering Hub in Cambridge
21st May 20257:00 amRNS-RNew Satellite User Terminal Chips
8th May 20257:00 amRNS-RInvestor Event - Mello 2025
7th May 20255:14 pmRNSHolding(s) in Company
14th Apr 20257:00 amRNS-RInvestment in Space Industry Fuelling Chip Demand
10th Apr 20257:00 amRNSMoU with European Satellite Operator
7th Apr 20257:00 amRNSTrading Update
27th Mar 20257:00 amRNS$18m 7 Year Design and Supply ASIC Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.